Acelrx pharmaceuticals announces presentation of investigator-initiated trial results comparing acelrx's sufentanil sublingual tablet (sst) versus intravenous opioids for postoperative pain at the anesthesiology® annual meeting 2022

Brigham and women's hospital study found that sst-treated patients had significantly lower pain scores in the post-operative care unit (pacu) compared with patients in the two intravenous opioid control groups following major spine surgery hayward, calif. , oct. 26, 2022 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the results of a 190-patient, investigator-initiated trial conducted at brigham and women's hospital in boston, ma, entitled, "the impact of sublingual sufentanil on postoperative pain control in patients undergoing spine surgery" (abstract # a4262), was presented at the anesthesiology® 2022 annual meeting, held october 21-25, 2022 in new orleans, la.
ACRX Ratings Summary
ACRX Quant Ranking